Thrombotic Microangiopathy as an Emerging Complication of Viral Vector–Based Gene Therapy
Kidney International Reports · 2024-07 · 9 (7) · 1995-2005
DOI: 10.1016/j.ekir.2024.04.024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Kidney International Reports, 2024-07. Verfasst von Nora Schwotzer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Service of Nephrology and Hypertension, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gene therapy has brought tremendous hope for patients with severe life-threatening monogenic diseases. Although studies have shown the efficacy of gene therapy, serious adverse events have also emerged, including thrombotic microangiopathy (TMA) following viral vector-based gene therapy. In this review, we briefly summarize the concept of gene therapy, and the immune response triggered by viral vectors. We also discuss the incidence, presentation, and potential underlying mechanisms, including complement activation, of gene therapy-associated TMA. Further studies are needed to better define the pathogenesis of this severe complication of gene therapy, and the optimal measures to prevent it.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Service of Nephrology and Hypertension, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Department of Immunology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
- Paris University, Paris, France.
- Paediatric Neurology Department, Necker Hospital, APHP Centre, Université Paris Cité, Paris, France.
- MDUK Oxford Neuromuscular Center and NIHR Oxford Biomedical Research Center, University of Oxford, Oxford, UK.
- Neuromuscular Center, Department of Pediatrics, University of Liege and University Hospital of Liege, Belgium.
Zitieren
APA
Schwotzer, N., El Sissy, C., Desguerre, I., Frémeaux-Bacchi, V., Servais, L., & Fakhouri, F. (2024). Thrombotic Microangiopathy as an Emerging Complication of Viral Vector–Based Gene Therapy. Kidney International Reports, 9(7), 1995-2005. https://doi.org/10.1016/j.ekir.2024.04.024
Vancouver
Schwotzer N, El Sissy C, Desguerre I, Frémeaux-Bacchi V, Servais L, Fakhouri F. Thrombotic Microangiopathy as an Emerging Complication of Viral Vector–Based Gene Therapy. Kidney International Reports. 2024;9(7):1995-2005. doi:10.1016/j.ekir.2024.04.024
BibTeX
@article{Schwotzer2024,
author = {Schwotzer, Nora and El Sissy, Carine and Desguerre, Isabelle and Frémeaux-Bacchi, Véronique and Servais, Laurent and Fakhouri, Fadi},
title = {Thrombotic Microangiopathy as an Emerging Complication of Viral Vector–Based Gene Therapy},
journal = {Kidney International Reports},
year = {2024},
volume = {9},
number = {7},
pages = {1995--2005},
doi = {10.1016/j.ekir.2024.04.024}
}
EUVIMED